查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球女性尿失禁治療設備市場-2022-2029
市場調查報告書
商品編碼
1140744

全球女性尿失禁治療設備市場-2022-2029

Global Female Urinary Incontinence Treatment Device Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

孕婦尿失禁患病率上升

根據 BMC 於 2022 年 1 月發布的一項研究，有 1243 名女性參加了研究。妊娠期尿失禁發生率為52.0%。大多數女性患有輕度或中度尿失禁。通過多元邏輯回歸確定了五個風險因素。孕前尿失禁是最強的預測因子，其次是陰道分娩史、咖啡消費、兒童尿崩症和尿路感染史。尿失禁對懷孕期間與健康相關的生活質量有顯著影響。只有 14.8% 的孕婦因排尿症狀尋求專業幫助。與尿失禁顯著相關的因素包括年齡組、胎齡、分娩次數、尿失禁史、便秘、最後一次分娩方式、尿路感染史和妊娠期肥胖。

此外，在預測期內，低價自有品牌產品的流行正在推動市場增長。由於女性壓力性尿失禁治療市場的產品種類繁多，小企業正在引起興趣並以低價銷售他們的產品。預計自有品牌的價格滲透率顯著降低將降低女性尿失禁壓力設備的平均總體價格。阻礙對昂貴產品的需求可能會阻礙全球女性壓力性尿失禁設備市場的增長。

地理滲透。

北美是預測期內的主要地區。

該研究按地區分析了全球市場的女性尿失禁設備市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

北美在 2021 年將主導全球女性尿失禁設備市場。在北美，預計美國在預測期內將出現大幅增長。在美國，女性尿失禁治療設備的潛在增長是由孕婦尿失禁、糖尿病引起的壓力性尿失禁、婦科疾病和絕經後婦女尿失禁的患病率上升推動的。

由於意識的提高、對醫療保健的投資增加以提供負擔得起的最佳設施以及社會經濟發展，預計亞太市場將在預測期內顯著擴大。在中國，隨著女性吸煙人數的增加，市場有望增長。新興國家的主要參與者增加投資預計將提振市場。由於認知度低、可支配收入低和醫療設施有限，預計中東和非洲市場將適度擴張。

競爭格局

Karl Storz、Johnson &Johnson、Coloplast、Boston Scientific、Teleflex、American Medical Solutions等是女性尿失禁設備市場的主要參與者，為全球市場的增長做出了貢獻。領先公司正在為女性尿失禁治療設備市場的全球增長採取新產品引進和擴張戰略。2022年5月，以女性為主導的公司聯想將推進女性盆底疾病數字療法的開發，讓1000名Leva處方醫生能夠獲得女性尿失禁的一線治療。Leva 是一種易於使用的骨盆健康管理系統，可減少尿失禁 (UI) 的症狀，包括膀胱過度活動症。Leva 在醫療保健專業人員中的迅速採用反映了他們希望改善 UI 保守治療的可及性。這種情況影響了美國 62% 的成年女性，並且隨著時間的推移往往會進展和惡化。2021 年 12 月，Caldera Medical 宣布 FDA 批准新的 Desara TVez 用於壓力性尿失禁。該公司擴大了其針對患有壓力性尿失禁的女性的治療選擇組合。Caldera Medical 與數十位領先的外科醫生合作，以增強易用性和患者安全性將 Desara TVez 帶入生活。2022 年 2 月，庫克的醫療業務被The Cooper Companies 收購，以在 MedSurg 部門內推廣庫克的整個生殖健康業務。The Cooper Companies 專注於女性健康和生殖解決方案，為 ART 之旅的每一步提供創新產品和服務。一些主要參與者正在遵循合併和合作戰略來擴展業務。例如，2020 年 10 月，Johnson & Johnson以約 65 億美元的價格完成了對 Momenta Pharmaceuticals 的收購。Momenta 在開發罕見病藥物方面有著令人印象深刻的記錄。一起拓展您的業務。

COVID-19 的影響將對全球女性尿失禁治療設備市場產生負面影響。

COVID-19 的爆發對全球女性尿失禁治療設備市場的增長產生了負面影響。對醫院服務的限制影響了尿失禁患者的專業檢查和手術治療。因此，COVID-19大流行對2020年女性尿失禁治療設備的市場價值產生了負面影響。

全球女性尿失禁治療設備市場報告提供大約 61 個市場數據表、50 個數字和 170 頁的結構。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

  • 按產品類型劃分的市場細分
  • 按使用材料劃分的市場細分
  • 最終用戶的市場細分
  • 區域市場細分

第四章市場動態

  • 市場影響因素
    • 促進者
      • 孕婦尿失禁患病率上升
      • 其他與壓力相關的尿失禁增加，如糖尿病、婦科疾病和絕經後婦女的尿失禁
      • 子宮切除術增加
      • 女性肥胖增加
    • 抑製劑
      • 女性對尿失禁治療缺乏認識
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 中的價格動態
  • 供需譜
  • 大流行期間與市場相關的政府努力
  • 製造商的戰略舉措
  • 概括

第 7 章按產品類型

  • 尿道裝置
  • 陰道內留置裝置

第 8 章 按所用材料

  • 發泡聚氨酯
  • 矽酮

第 9 章最終用戶

  • 醫院
  • 專科診所
  • 門診手術中心

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第 11 章 競爭格局

  • 競爭情景
  • 市場/份額分析
  • 併購分析

第十二章公司簡介

  • Bard Medical
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Karl Storz
  • Johnson & Johnson
  • Coloplast
  • Boston Scientific
  • Teleflex
  • AMERICAN MEDICAL SOLUTIONS
  • Ethicon, Inc.
  • Caldera Medical Inc
  • COOK MEDICAL（*LIST NOT EXHAUSTIVE*）

第 13 章 重要注意事項

第 14 章 數據管理

簡介目錄
Product Code: DMMD3131

Market Overview

Female Urinary Incontinence Treatment Device Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Female urinary incontinence has been diagnosed as a condition that causes involuntary urination. Urinary incontinence or stress urinary incontinence typically occurs during physical activities, such as sneezing, coughing, running, or even during weightlifting, as these activities exert pressure on the urinary bladder. Urinary urge and stress incontinence are different, as the former occurs when the bladder muscles are contracted. Urinary stress incontinence affects women more than men and is mostly due to weak muscle sphincter, which can lead to social isolation. Female urinary incontinence is of two types: the first is urethral hypermobility and the second is due to an inherent sphincter deficiency. In the case of urethra hypermobility, increased abdominal pressure changes the position of the urethra. On the other hand, in the inherent sphincter of the deficiency, the sphincter has lost its ability to seal the deficiency of the intestinal sphincter. The major factors propelling the growth of the female urinary incontinence treatment device market are the rising prevalence of urinary incontinence in pregnant women, stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women and rising cases of hysterectomy. Moreover, the rising incidence of obesity in the female population is the major factor expected to deliver significant growth to the market in the upcoming period.

Market Dynamics: Rising prevalence of urinary incontinence in pregnant women

According to the research published by BMC in January 2022, 1243 women were enrolled in the study. The prevalence of urinary incontinence during pregnancy was 52.0%. Most women suffer from mild or moderate incontinence. Multiple logistic regressions identified five risk factors. Urinary incontinence before pregnancy was the strongest predictor of incontinence, followed by the history of vaginal birth, coffee consumption, childhood enuresis and history of urinary tract infection. Urinary incontinence had a significant impact on health-related quality of life during pregnancy. Only 14.8% of pregnant women sought professional help for urinary symptoms. Factors significantly associated with urinary incontinence included age group, gestational age, parity, prior urinary incontinence, constipation, last childbirth mode of delivery, previous urinary tract infection, and body mass index during pregnancy.

Moreover, an increase in the penetration of private-label brands at much lower prices drives market growth in the forecast period. Due to the presence of a wide range of products on the market for female stress urinary incontinence treatment devices, small players are gaining interest and selling their products at lower prices. An increase in the penetration of private-label brands at much lower prices is expected to reduce the average overall price of female urinary incontinence stress treatment devices. It is likely to constrain the growth of the global market for female stress urinary incontinence treatment devices, as it is likely to hinder demand for expensive products.

Market Segmentation: The internal vaginal device segment is projected to be the dominant segment in the market during the forecast period.

Based on the product type, the female urinary incontinence treatment device market has been classified into urethral devices and internal vaginal devices.

The internal vaginal devices segment can be further categorized into traditional devices and custom-made devices. Urinary stress incontinence is significantly more common in women than in men. Female urinary incontinence treatment device occurs when pelvic floor muscles or urinary sphincter are likely to lose strength, either due to women's childbirth or men's prostate surgery. Thus, due to such factors, the internal vaginal device is expected to hold a dominant position in the market.

The female urinary incontinence treatment device is segmented based on end-user, which includes hospitals, speciality clinics, and ambulatory surgical centers.

The hospital pharmacies segment is expected to hold a significant market share in the female urinary incontinence treatment device market. Hospital in the end-user segment is expected to have a significant share of the global market for urinary incontinence devices due to the large patient population treated in hospitals suffering from urinary incontinence. Moreover, hospitals are expected to grow with the highest CAGR in the forthcoming period with the rise in technological advancement in the industry.

Furthermore, the female urinary incontinence treatment device is segmented on the basis of material used, which includes polyurethane foam and silicone. Polyurethane foam is the dominating segment along with projected to grow with the highest CAGR in the forthcoming period.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the female urinary incontinence treatment device market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global female urinary incontinence treatment device market in 2021. In North America, the U.S. is expected to represent considerable growth during the forecast period. In the U.S., the female urinary incontinence treatment device is expected to have potential growth due to the rising prevalence of urinary incontinence in pregnant women and stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women.

The Asia-Pacific market is projected to expand significantly during the forecast period due to increased awareness, increased investment in health care to provide optimum facilities at affordable cost, and socio-economic development. The increase in the number of women smoking in China is expected to boost the market. Increased investment by prominent players in developing countries is expected to boost the market. The Middle East & Africa market is projected to expand slowly due to a lack of awareness, low disposable income, and limited healthcare facilities.

Competitive Landscape:

The key female urinary incontinence treatment device market players contributing to the global market's growth include Karl Storz, Johnson & Johnson, Coloplast, Boston Scientific, Teleflex, and American Medical Solutions, among others. The major players are adopting new product launches and expansion strategies for global growth in the female urinary incontinence treatment device market. In May 2022, Renovia, a women-led company, advances the development of digital therapeutics for female pelvic floor disorders access to first-line treatment for female urinary incontinence with 1,000 leva prescribers. Leva is a pelvic health system that is easy to use and that help woman decreases the symptoms of urinary incontinence (UI) symptoms, including overactive bladder. Leva's accelerated adoption among healthcare providers reflects their desire to improve access to conservative treatment for UI. This condition affects 62% of adult women in the U.S. and tends to progress and worsen over time. In December 2021, Caldera Medical announced FDA approval for the New Desara TVez for Stress Urinary Incontinence. The company expands its product portfolio of treatment options for women suffering from Stress Urinary Incontinence. Caldera Medical collaborated with dozens of leading surgeons to bring enhanced ease of use and patient safety to life in the form of Desara TVez. In February 2022, Cook's medical business was acquired by CooperCompanies to sell the entirety of Cook's Reproductive Health business within the MedSurg division. Cooper Companies focuses on women's health and fertility solutions, providing innovative products and services for every step in the ART journey. Some key players follow merger and collaboration strategies to expand their business. For instance, in October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals, Inc. for approximately $6.5 billion. Momenta has made excellent progress in developing its medicines for rare diseases. Together they expand their business.

COVID-19 Impact: Negative impact on the global female urinary incontinence treatment device market.

The outbreak of COVID-19 has negatively impacted the growth of the female urinary incontinence treatment device market globally. Restrictions on hospital services have affected the specialized investigation and surgical management of patients with urinary incontinence. Therefore, the COVID-19 pandemic had a negative impact on the market value of the female urinary incontinence treatment device market in 2020.

The global female urinary incontinence treatment device market report would provide an access to approximately 61 market data tables, 50 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Material used
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of urinary incontinence in pregnant women
      • 4.1.1.2. Stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women
      • 4.1.1.3. Rising cases of hysterectomy
      • 4.1.1.4. Rising incidence of obesity in the female population
    • 4.1.2. Restraint
      • 4.1.2.1. Lack of awareness among women regarding urinary incontinence treatment
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Urethral devices
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Internal vaginal devices

8. By Material used

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used Segment
  • 8.3. Market Attractiveness Index, By Material Segment
    • 8.3.1. Polyurethane Foam
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Silicone

9. By End user

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user Segment
  • 9.3. Market Attractiveness Index, By End user Segment
    • 9.3.1. Hospitals
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Specialty clinics
    • 9.3.3. Ambulatory surgical centers

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bard Medical*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Karl Storz
  • 12.3. Johnson & Johnson
  • 12.4. Coloplast
  • 12.5. Boston Scientific
  • 12.6. Teleflex
  • 12.7. AMERICAN MEDICAL SOLUTIONS
  • 12.8. Ethicon, Inc.
  • 12.9. Caldera Medical Inc
  • 12.10. COOK MEDICAL (*LIST NOT EXHAUSTIVE*)

13. Premium Insights

14. DataM Intelligence Analysis

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us